\n
\n \n Generated Narrative\n \n
\n
\n \n Id\n \n : equilidem-basics\n
\n
\n \n Identifier\n \n : Equilidem25\n
\n
\n \n Combined Pharmaceutical Dose Form\n \n :\n \n tablet\n \n
\n
\n \n Indication\n \n : Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.\n
\n
\n \n Legal Status Of Supply\n \n :\n \n Prescription only medicine\n \n
\n
\n \n Classification\n \n :\n \n ATC: B01A\n \n
\n
\n \n Ingredient\n \n :\n
\n
\n - \n \n Equilidonium Phosphate\n \n
\n - \n \n Calcium Carbonate\n \n
\n
\n
\n Names\n
\n
\n \n \n -\n | \n \n \n Product Name\n \n | \n
\n \n \n *\n | \n \n Equilidem 2.5 mg film-coated tablets\n | \n
\n
\n
\n Cross References\n
\n
\n \n \n -\n | \n \n \n Product\n \n | \n
\n \n \n *\n | \n \n Link to generic equivalent\n | \n
\n
\n
\n Manufacturing/Business Operations\n
\n
\n \n \n -\n | \n \n \n Manufacturer\n \n | \n
\n \n \n *\n | \n \n \n EquiliDrugCo Inc.\n \n | \n
\n
\n
"
];
fhir:MedicinalProductDefinition.identifier [
fhir:index 0;
fhir:Identifier.system [ fhir:value "http://example.org.uk/fhir/product" ];
fhir:Identifier.value [ fhir:value "Equilidem25" ]
];
fhir:MedicinalProductDefinition.combinedPharmaceuticalDoseForm [
fhir:CodeableConcept.coding [
fhir:index 0;
fhir:Coding.system [ fhir:value "http://example.org.uk/fhir/dosefom" ];
fhir:Coding.code [ fhir:value "tablet" ]
]
];
fhir:MedicinalProductDefinition.indication [ fhir:value "Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class >= II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults."];
fhir:MedicinalProductDefinition.legalStatusOfSupply [
fhir:CodeableConcept.coding [
fhir:index 0;
fhir:Coding.system [ fhir:value "http://example.org.uk/fhir/legalstatusofsupply" ];
fhir:Coding.code [ fhir:value "POM" ];
fhir:Coding.display [ fhir:value "Prescription only medicine" ]
]
];
fhir:MedicinalProductDefinition.classification [
fhir:index 0;
fhir:CodeableConcept.coding [
fhir:index 0;
fhir:Coding.system [ fhir:value "http://www.whocc.no/atc/example" ];
fhir:Coding.code [ fhir:value "B01A" ]
]
];
fhir:MedicinalProductDefinition.ingredient [
fhir:index 0;
fhir:CodeableConcept.text [ fhir:value "Equilidonium Phosphate" ]
], [
fhir:index 1;
fhir:CodeableConcept.text [ fhir:value "Calcium Carbonate" ]
];
fhir:MedicinalProductDefinition.name [
fhir:index 0;
fhir:MedicinalProductDefinition.name.productName [ fhir:value "Equilidem 2.5 mg film-coated tablets" ]
];
fhir:MedicinalProductDefinition.crossReference [
fhir:index 0;
fhir:MedicinalProductDefinition.crossReference.product [
fhir:CodeableReference.reference [
fhir:link